[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-001", "question": "A 27-year-old G1P0 at 9 weeks' gestation presents with intractable nausea and vomiting, 7-kg weight loss, new-onset jaundice, and confusion over 3 days. She has no prior liver disease or alcohol use. Vitals: T 37.2°C, HR 122, BP 100/62, RR 18, SpO2 98% RA. Exam: scleral icterus, moderate right upper quadrant tenderness without rebound, asterixis. Labs: Na 132, K 3.1, bicarbonate 19, creatinine 1.2 mg/dL (baseline 0.6), AST 545 U/L, ALT 510 U/L, ALP 225 U/L, total bilirubin 12.4 mg/dL (direct 8.1), INR 2.6, ammonia 102 µmol/L, β-hCG markedly elevated for gestational age, thyroid studies: TSH low, free T4 and T3 mildly elevated. Abdominal ultrasound: single live intrauterine pregnancy, normal hepatic and portal vasculature, no biliary dilation, mild fatty liver change. Viral hepatitis serologies and autoimmune markers are pending. She is receiving IV fluids and antiemetics but continues to deteriorate neurologically. Which of the following is the most appropriate immediate next management step?", "options": ["Administer high-dose IV methylprednisolone and defer pregnancy decisions until serologies return", "Urgently proceed with uterine evacuation and initiate N-acetylcysteine infusion", "Start high-dose IV thiamine and parenteral nutrition while continuing pregnancy", "List for emergent liver transplantation without altering pregnancy status", "Administer propylthiouracil and beta-blockers to treat probable gestational thyrotoxicosis and reassess"], "answer": "B", "answer_index": 1, "explanation": "This presentation is most consistent with hyperemesis gravidarum-associated acute liver failure with encephalopathy and coagulopathy; maternal survival takes precedence, and rapid uterine evacuation plus N-acetylcysteine offers the best chance to reverse fulminant hepatic injury. Steroids (A) address autoimmune hepatitis, which is unconfirmed and too slow. Thiamine and nutrition (C) are supportive but insufficient in fulminant failure with encephalopathy. Immediate transplantation listing (D) may be needed but should follow rapid removal of the precipitating factor. Treating mild gestational thyrotoxicosis alone (E) will not address the primary life-threatening hepatic process.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with signs of acute liver failure (ALF) in the first trimester of pregnancy, characterized by coagulopathy (INR 2.6), jaundice (Total Bilirubin 12.4 mg/dL), and hepatic encephalopathy (confusion, asterixis, elevated ammonia). The clinical context includes intractable nausea/vomiting (Hyperemesis Gravidarum), markedly elevated $\\beta$-hCG, and findings consistent with gestational transient thyrotoxicosis (suppressed TSH, elevated free T4/T3, lack of prior thyroid history).\n\nThe differential diagnosis for severe liver dysfunction in pregnancy includes viral hepatitis, drug-induced liver injury, and pregnancy-specific dermatoses/liver diseases. While Hyperemesis Gravidarum (HG) typically causes only mild aminotransferase elevations, rare cases of severe HG can progress to malnutrition, jaundice, and frank liver failure. The patient's condition is deteriorating (\"continuing to deteriorate neurologically\") despite standard supportive care (fluids, antiemetics).\n\nManagement Analysis:\n*   Options A, C: While corticosteroids (A) are a second-line treatment for refractory HG, and thiamine/nutrition (C) are critical for preventing Wernicke's encephalopathy and treating malnutrition, this patient has progressed to fulminant liver failure. \"Deferring pregnancy decisions\" or \"continuing pregnancy\" in the face of progressive maternal organ failure and encephalopathy carries an unacceptably high risk of maternal mortality.\n*   Option D: Liver transplantation is reserved for irreversible liver failure. In pregnancy-related liver dysfunction, evacuation of the uterus often facilitates rapid recovery of hepatic function. Listing for transplant without addressing the precipitating cause (the pregnancy) is inappropriate.\n*   Option E: The patient has gestational transient thyrotoxicosis mediated by high hCG levels, not Graves' disease. Propylthiouracil (PTU) is not indicated for this condition. Furthermore, PTU has a Black Box Warning for severe liver injury and acute liver failure; administering it to a patient with existing liver failure and INR 2.6 is absolutely contraindicated.\n*   Option B: When hyperemesis gravidarum or gestational trophoblastic activity leads to severe end-organ damage (such as refractory liver failure) threatening maternal life, the definitive management is uterine evacuation. Additionally, N-acetylcysteine (NAC) is indicated for non-acetaminophen acute liver failure to improve transplant-free survival by improving microcirculatory blood flow and scavenging free radicals. This option addresses both the etiology (pregnancy) and the immediate hepatic crisis.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-002", "question": "A 63-year-old man with long-standing hypertension and ischemic cardiomyopathy (EF 30%) presents with acute right hemiplegia and aphasia 45 minutes after symptom onset. NIHSS is 18. Noncontrast CT head shows no hemorrhage. CT angiography shows left M1 occlusion with favorable collaterals; CT perfusion suggests a large salvageable penumbra. ECG shows sinus rhythm with frequent PVCs. High-sensitivity troponin is mildly elevated and flat on serial testing. You plan IV thrombolysis and urgent mechanical thrombectomy. Which of the following additional acute management steps is most appropriate?", "options": ["Initiate IV unfractionated heparin infusion before mechanical thrombectomy due to high cardioembolic risk", "Administer IV labetalol to reduce blood pressure to <140/90 mm Hg prior to thrombolysis", "Start high-dose statin and delay any antiplatelet therapy until 24 hours after thrombolysis", "Begin dual antiplatelet therapy with aspirin and clopidogrel immediately after thrombolysis", "Place an intra-aortic balloon pump preemptively to support cerebral perfusion during thrombectomy"], "answer": "C", "answer_index": 2, "explanation": "The correct step is to start high-intensity statin immediately and delay antiplatelets until 24 hours after thrombolysis and repeat imaging, per acute ischemic stroke guidelines. Heparin before thrombectomy (A) increases hemorrhagic risk with no proven benefit. Lowering BP below 140/90 (B) before tPA is too aggressive and can worsen cerebral perfusion; only treat if >185/110 to that threshold. Dual antiplatelets immediately after tPA (D) markedly increases hemorrhage risk. Intra-aortic balloon pump (E) has no role in this setting and carries procedural risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Here is the evaluation of the options based on current guidelines for the management of acute ischemic stroke:\n\n1.  Patient Status: The patient is having a large vessel occlusion stroke, is within the time window for both IV thrombolysis (IVT) and mechanical thrombectomy (MT), and has a large salvageable penumbra.\n2.  Plan: IV thrombolysis and Mechanical Thrombectomy.\n\nAnalysis of Options:\n*   A. Initiate IV unfractionated heparin infusion before mechanical thrombectomy: Full-dose anticoagulation (heparin) is not recommended during the acute phase of ischemic stroke, specifically within 24 hours of IV thrombolysis, due to the significantly increased risk of intracranial hemorrhage.\n*   B. Administer IV labetalol to reduce blood pressure to <140/90 mm Hg: While blood pressure must be controlled prior to IV thrombolysis, the guideline-recommended target is <185/110 mm Hg. Reducing blood pressure aggressively to <140/90 mm Hg in the setting of an acute occlusion may compromise collateral flow and reduce perfusion to the ischemic penumbra, potentially worsening the stroke.\n*   C. Start high-dose statin and delay any antiplatelet therapy until 24 hours after thrombolysis: This is the correct management. Current AHA/ASA guidelines state that antiplatelet and anticoagulant therapies should not be administered for 24 hours following treatment with IV thrombolytics (alteplase/tenecteplase) to minimize bleeding risk (specifically hemorrhagic transformation). A follow-up scan is usually performed at 24 hours to rule out hemorrhage before starting these agents. Initiating high-dose statin therapy is appropriate for secondary prevention.\n*   D. Begin dual antiplatelet therapy with aspirin and clopidogrel immediately after thrombolysis: Administering antiplatelet agents within 24 hours of IV thrombolysis is contraindicated due to bleeding risk.\n*   E. Place an intra-aortic balloon pump preemptively: There is no indication of cardiogenic shock (hypotension/hypoperfusion) in the vignette. The patient has a history of cardiomyopathy, but without evidence of collapse, placing an IABP is invasive and unnecessary, and stroke patients typically require elevated blood pressure for cerebral perfusion.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-003", "question": "A 34-year-old woman with SLE (malar rash, arthritis, class III lupus nephritis on biopsy) on mycophenolate and low-dose prednisone presents with 3 months of progressive exertional dyspnea and dry cough. She has no smoking history. Vitals: HR 96, BP 112/70, RR 18, SpO2 94% RA. Exam: fine bibasilar crackles, no peripheral edema. Labs: creatinine 1.0 mg/dL, ANA 1:640 homogeneous, anti-dsDNA mildly elevated, complements low, ESR 18 mm/hr, CRP 2 mg/L. PFTs: FVC 65% predicted, FEV1/FVC 0.82, DLCO 40% predicted. HRCT: diffuse ground-glass opacities with scattered areas of consolidation and traction bronchiectasis, predominantly in lower lobes, no honeycombing. BAL: lymphocytic predominance, cultures negative. Echocardiogram: normal LV function, PASP 30 mm Hg. Which of the following is the most appropriate next step in management?", "options": ["Escalate mycophenolate dose and add high-dose oral prednisone without further diagnostics", "Switch mycophenolate to cyclophosphamide and simultaneously list for lung transplantation", "Perform surgical lung biopsy to distinguish organizing pneumonia from NSIP", "Add rituximab while continuing mycophenolate at the same dose", "Initiate nintedanib in addition to current immunosuppression for progressive fibrosing ILD"], "answer": "E", "answer_index": 4, "explanation": "This is SLE-associated progressive fibrosing interstitial lung disease with traction bronchiectasis and physiologic restriction despite immunosuppression; nintedanib has evidence for slowing decline in progressive fibrosing ILDs, including CTD-ILD. Blind escalation of steroids/mycophenolate (A) risks toxicity without clear additional benefit. Routine upfront lung transplant listing (B) is premature. Lung biopsy (C) is high risk and unlikely to alter management given established CTD-ILD pattern. Rituximab (D) can be considered, but antifibrotic therapy specifically targets the progressive fibrosing phenotype and is strongly indicated here.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient with SLE presents with subacute, progressive shortness of breath and imaging findings characteristic of SLE-associated interstitial lung disease (ILD). The High-Resolution CT (HRCT) findings of diffuse ground-glass opacities (GGO), consolidation, and traction bronchiectasis (likely in a lower lobe distribution) are highly suggestive of Nonspecific Interstitial Pneumonia (NSIP), potentially with overlapping Organizing Pneumonia (OP). The BAL rules out infection, which is a crucial first step.\n\nThe key to management here is recognizing that the patient has active inflammatory lung disease (evidenced by GGOs, consolidation, and subacute course) and is currently under-treated with only *low-dose* prednisone.\n\n*   Option A: Escalate mycophenolate dose and add high-dose oral prednisone without further diagnostics.\n    *   High-dose corticosteroids (e.g., 1 mg/kg or pulse therapy) are the cornerstone of induction therapy for symptomatic, inflammatory SLE-ILD (NSIP/OP pattern). This patient is currently on low-dose prednisone, which is insufficient for active pneumonitis.\n    *   Mycophenolate mofetil (MMF) is a first-line agent for SLE-ILD (and her lupus nephritis). Since the patient developed symptoms while on therapy, it is reasonable to ensure she is on the maximally tolerated therapeutic dose (e.g., 3 g/day) before switching agents, especially in combination with the new high-dose steroid regimen.\n    *   \"Without further diagnostics\" is appropriate regarding biopsy, as the clinical and radiologic picture confirms SLE-ILD and infection has been excluded.\n\n*   Option B: Switch mycophenolate to cyclophosphamide and simultaneously list for lung transplantation.\n    *   While cyclophosphamide (CYC) is used for severe or refractory SLE-ILD, the second part of this option makes it incorrect. Listing for lung transplantation is reserved for patients with end-stage, irreversible fibrosis who have failed maximal medical therapy. This patient has GGOs (reversible inflammation) and has not yet received high-dose steroids or a trial of CYC. Truly irreversible fibrosis is not yet established.\n\n*   Option C: Perform surgical lung biopsy to distinguish organizing pneumonia from NSIP.\n    *   Surgical lung biopsy carries significant morbidity and mortality risks, especially in patients with respiratory compromise (DLCO 40%). Distinguishing between NSIP and OP in an SLE patient rarely alters management, as both respond to corticosteroids and immunosuppression. The clinical and HRCT features are sufficient for a working diagnosis.\n\n*   Option D: Add rituximab while continuing mycophenolate at the same dose.\n    *   Rituximab is typically reserved for refractory cases (after failing MMF and/or CYC). Furthermore, adding rituximab without initiating high-dose corticosteroids would fail to address the acute inflammatory pneumonitis that is causing her current decompensation.\n\n*   Option E: Initiate nintedanib in addition to current immunosuppression for progressive fibrosing ILD.\n    *   Nintedanib is an antifibrotic agent. While approved for progressive fibrosing ILDs, this patient's imaging (GGOs, consolidation) and subacute course suggest an active inflammatory process driven by SLE. Is it imperative to treat the inflammation with immunosuppression first. Nintedanib does not treat the underlying autoimmunity effectively on its own and is usually an add-on therapy for fibrosis continuing despite immunomodulation.\n\nTherefore, the most appropriate immediate management is to treat the active inflammation with high-dose corticosteroids and optimize the current immunosuppressive regimen.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-004", "question": "A 51-year-old woman with poorly controlled type 2 diabetes and prior pelvic radiation for cervical cancer presents with 5 days of fever, worsening lower abdominal pain, and foul vaginal discharge. She is hypotensive and tachycardic. Exam: diffuse lower abdominal tenderness with guarding, necrotic friable tissue at the posterior vaginal fornix with gas bubbles and crepitus extending toward the rectovaginal septum. Labs: WBC 19,000/µL, lactate 4.5 mmol/L, creatinine 2.1 mg/dL. CT abdomen/pelvis with contrast: extensive gas in the pelvis tracking along fascial planes into the perineum, no discrete drainable collection, suspected uterine and vaginal wall necrosis. Blood cultures are drawn, and broad-spectrum IV antibiotics and aggressive fluids are started. Which is the most appropriate next step?", "options": ["Urgent total abdominal hysterectomy with wide radical debridement of necrotic pelvic and perineal tissue", "Percutaneous CT-guided drainage of gas-containing pelvic spaces plus continued maximal antibiotics", "Hyperbaric oxygen therapy as a temporizing measure before any surgical intervention", "Emergent exploratory laparotomy limited to diagnostic assessment and peritoneal lavage", "Conservative management with antibiotics and close ICU monitoring to avoid worsening radiation injury"], "answer": "A", "answer_index": 0, "explanation": "The clinical picture is necrotizing pelvic soft tissue infection (type I Fournier-like process) involving uterus and vagina in a radiated field, requiring immediate radical surgical debridement including hysterectomy. Percutaneous drainage (B) is inadequate for necrotizing fasciitis. Hyperbaric oxygen (C) may be adjunctive but never replaces urgent debridement. Exploratory laparotomy without aggressive debridement (D) fails to control source. Conservative management (E) carries an almost universally fatal risk in necrotizing infections.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Based on the clinical presentation, the patient is suffering from a necrotizing soft tissue infection (NSTI) involving the pelvis and likely the uterus (gangrenous myometritis or mixed anaerobic infection), evidenced by fever, shock (hypotension, tachycardia), crepitus, necrotic tissue at the vaginal fornix, and gas tracking along fascial planes on CT. The patient's history of diabetes and pelvic radiation places her at high risk for vascular compromise and severe infection.\n\n1.  Diagnosis: The presence of gas tracking along fascial planes, crepitus, and frank necrosis characterizes a surgical emergency (like necrotizing fasciitis or Fournier's gangrene). The \"suspected uterine and vaginal wall necrosis\" suggests the uterus is a primary source or heavily involved.\n2.  Management Principles: The gold standard treatment for any necrotizing infection is immediate and aggressive surgical debridement. Antibiotics alone are ineffective because they cannot penetrate dead tissue/fascicles where bacteria thrive and blood supply is cut off.\n3.  Evaluation of Options:\n    *   Option A: This is the correct text step. Source control is mandated. Because the uterus and vaginal wall are necrotic, a hysterectomy is required to remove the source of sepsis, along with wide debridement of any other involved tissues (fascia, perineum).\n    *   Option B: CT-guided drainage is reserved for abscesses (fluid collections). The CT shows \"no discrete drainable collection,\" and drainage does not address necrotic tissue.\n    *   Option C: Hyperbaric oxygen makes sense as an adjunct *after* surgery or in very specific instances, but it should never delay surgical debridement in a patient with septic shock and necrotizing fasciitis.\n    *   Option D: Exploratory laparotomy is correct in approach, but \"limited to diagnostic assessment and peritoneal lavage\" is insufficient. Lavage does not remove gangrenous organs. The necrotic tissue must be resected.\n    *   Option E: Conservative management in the presence of necrotizing infection and septic shock leads to nearly 100% mortality.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-005", "question": "A 76-year-old man with permanent atrial fibrillation on apixaban, CKD stage 3b, and prior TIA undergoes TAVR for symptomatic severe aortic stenosis. Preprocedure echo: EF 55%, no intracardiac thrombus, moderate MAC, mild-moderate MR. Postprocedure, he develops acute severe dyspnea and hypotension 2 hours later. Echo: hyperdynamic LV with near-complete mid-cavity obliteration in systole, peak LVOT gradient 80 mm Hg, systolic anterior motion (SAM) of the mitral valve, severe MR, intact TAVR function. Which of the following is the most appropriate immediate management?", "options": ["Start high-dose IV furosemide and nitroprusside to rapidly reduce preload and afterload", "Administer aggressive IV crystalloids and start a phenylephrine infusion while reducing inotropes", "Urgently return to the cath lab for balloon post-dilatation of the TAVR prosthesis", "Begin IV milrinone infusion to augment contractility and improve forward flow", "Perform emergent surgical myectomy with mitral valve repair"], "answer": "B", "answer_index": 1, "explanation": "This is dynamic LVOT obstruction with SAM and severe MR precipitated by TAVR and low preload; management mirrors hypertrophic obstructive physiology-volume expansion and pure alpha-agonist (phenylephrine) to increase afterload while avoiding inotropes. Diuresis and vasodilators (A) and inotropes (D) worsen obstruction. Post-dilatation of the valve (C) is not indicated as prosthetic function is normal. Emergent surgery (E) is reserved for refractory cases after optimal medical hemodynamic management has failed.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with hemodynamic instability (hypotension and dyspnea) shortly after Transcatheter Aortic Valve Replacement (TAVR). The echocardiogram reveals a classic \"suicide LV\" scenario: a hyperdynamic left ventricle with cavity obliteration, a high LVOT gradient, and Systolic Anterior Motion (SAM) of the mitral valve causing severe mitral regurgitation (MR).\n\nThis physiology represents dynamic Left Ventricular Outflow Tract (LVOT) obstruction. The relief of the fixed afterload (the aortic stenosis) leads to hyperdynamic contraction. If the patient is hypovolemic or has underlying septal hypertrophy/small LV cavity, the vigorous contraction brings the ventricular walls together and pulls the anterior mitral leaflet into the outflow tract (SAM), obstructing flow and preventing mitral coaptation (causing MR).\n\nThe management goals for acute dynamic LVOT obstruction are:\n1.  Increase Preload: Expand the LV cavity size to keep the outflow tract open.\n2.  Increase Afterload: Increase resistance to ejection to reduce the pressure gradient and splint the LVOT open.\n3.  Decrease Contractility: Reduce the hyperdynamic nature of the systole.\n4.  Decrease Heart Rate: Increase filling time (though this patient is in AFib, rate control is beneficial).\n\nLet's evaluate the options:\n*   A. Start high-dose IV furosemide and nitroprusside: Furosemide reduces preload, and nitroprusside reduces afterload. This would shrink the LV cavity and lower resistance, drastically worsening the obstruction and potentially leading to cardiac arrest.\n*   B. Administer aggressive IV crystalloids and start a phenylephrine infusion while reducing inotropes: IV fluids increase preload. Phenylephrine is a pure alpha-agonist that increases Systemic Vascular Resistance (afterload) without increasing cardiac contractility (unlike norepinephrine or epinephrine). Reducing inotropes prevents worsening of the hyperdynamic state. This is the correct strategy.\n*   C. Urgently return to the cath lab for balloon post-dilatation: The echo shows intact TAVR function. The gradient is subvalvular (LVOT), not valvular. Post-dilation is unnecessary and does not treat the underlying dynamic obstruction.\n*   D. Begin IV milrinone infusion: Milrinone provides inotropy (increased contractility) and vasodilation (decreased afterload). Both effects would severely exacerbate the obstruction and SAM.\n*   E. Perform emergent surgical myectomy: While surgery treats HOCM, immediate management of acute post-TAVR instability is medical resuscitation. Stabilizing the patient with volume and pressors is the priority. Surgery is extremely high risk in this acute setting and used only if conservative measures fail completely or later in the course.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-006", "question": "A 42-year-old man who injects drugs presents with 10 days of fever, severe back pain, and new right leg weakness. Vitals: T 38.8°C, HR 108, BP 122/74. Exam: midline lumbar tenderness, right leg 3/5 strength with hyperreflexia, left leg 5/5, intact sensation, no bowel/bladder symptoms. Labs: WBC 15,000/µL, ESR 96 mm/hr, CRP 120 mg/L. Blood cultures: MRSA in 2/2 sets. MRI lumbar spine with contrast: dorsal epidural collection L2-L4 with significant canal compromise and enhancement consistent with epidural abscess, plus adjacent vertebral osteomyelitis; no discrete psoas abscess. He is started on IV vancomycin. Neurosurgery feels surgery is high risk due to severe cardiomyopathy (EF 20%) and active drug use, recommending medical therapy unless deterioration. What is the most appropriate next step?", "options": ["Continue IV vancomycin alone with close neurologic monitoring for at least 6 weeks", "Add rifampin to vancomycin to enhance penetration into epidural space and bone", "Perform urgent surgical decompression and drainage despite high perioperative risk", "Switch to daptomycin plus ceftaroline to provide broader MRSA coverage", "Place percutaneous CT-guided drain into the epidural collection to avoid open surgery"], "answer": "C", "answer_index": 2, "explanation": "He has spinal epidural abscess with evolving motor deficit and significant canal compromise; urgent surgical decompression and drainage is indicated despite elevated operative risk, as delay risks permanent paralysis. Medical therapy alone (A, B, D) is inadequate once neurologic deficits are present. Percutaneous drainage (E) is not appropriate for epidural abscess causing cord compression, as it rarely achieves effective decompression or safe access to the epidural space.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "This clinical scenario describes a patient with a Spinal Epidural Abscess (SEA) caused by MRSA, complicated by significant neurological deficits (right leg weakness, hyperreflexia). The standard of care for SEA with neurological compromise is urgent surgical decompression and source control (drainage) combined with systemic antibiotics. This is because neurological recovery is inversely related to the duration of compression; delay can lead to permanent paralysis.\n\nHowever, the patient has significant comorbidities (severe cardiomyopathy with EF 20%) that make open surgery (general anesthesia, prone positioning, blood loss) extremely high risk. The neurosurgeon has recommended medical management due to this risk.\n\nWe must evaluate the options to balance the need for spinal cord decompression/source control against the patient's perioperative mortality risk:\n\n*   Option A (Medical management alone): While valid for patients who are stable with no neurological deficits, this patient has a dense motor deficit (3/5 strength) and significant canal compromise. Relying solely on antibiotics is associated with higher rates of treatment failure and permanent neurological morbidity compared to drainage.\n*   Option B (Add rifampin): There is no strong evidence to support the routine addition of rifampin for native vertebral osteomyelitis/SEA. It is primarily used for biofilm-associated infections (prosthetics).\n*   Option C (Urgent open surgery): While this addresses the neurological issue, the perioperative mortality risk given the EF of 20% is prohibitive. \"Life over limb\" principles often apply, but there is a safer alternative for decompression.\n*   Option D (Switch antibiotics): Vancomycin is the standard first-line therapy for MRSA bacteremia and SEA. There is no evidence of treatment failure (e.g., persistent bacteremia despite adequate levels) at this early stage to warrant switching to daptomycin/ceftaroline.\n*   Option E (Percutaneous CT-guided drainage): This is the most appropriate next step. The MRI indicates a dorsal collection, which is accessible percutaneously. Guidelines (such as IDSA 2015 for Vertebral Osteomyelitis) specifically suggest that for patients who are poor candidates for open surgery, CT-guided aspiration/drainage should be attempted. This allows for source control (reducing bacterial burden) and decompression of the spinal canal (alleviating immediate pressure on the cord) while avoiding the hemodynamic risks of open surgery.\n\nTherefore, percutaneous drainage bridges the gap between the need for decompression and the high surgical risk.\n\nThe answer is (E)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-007", "question": "A 31-year-old woman presents with severe headaches, transient visual obscurations, and pulsatile tinnitus 6 months postpartum. She has gained 20 kg during and after pregnancy. BMI is 38 kg/m². Exam: bilateral papilledema, full strength, no focal deficits. MRI brain with and without contrast is normal. MRV shows smooth tapering and non-visualization of the terminal right transverse sinus with small caliber sigmoid sinus and jugular bulb; the left transverse sinus is dominant and widely patent. Lumbar puncture: opening pressure 34 cm H₂O, normal CSF studies. She is started on acetazolamide and advised weight loss but continues to have progressive visual field loss on serial perimetry over 8 weeks. What is the most appropriate next step in management?", "options": ["Place a ventriculoperitoneal shunt to lower intracranial pressure", "Perform right transverse sinus stenting across the narrowed segment", "Initiate high-dose oral topiramate instead of acetazolamide", "Perform optic nerve sheath fenestration to protect vision", "Start therapeutic anticoagulation for presumed chronic venous sinus thrombosis"], "answer": "D", "answer_index": 3, "explanation": "The patient has idiopathic intracranial hypertension with rapidly progressive visual loss despite maximal medical therapy; optic nerve sheath fenestration is the preferred intervention to promptly protect vision. VP shunting (A) is an option but has higher long-term failure and complication rates and is usually considered after or when ONSF is not feasible. Transverse sinus stenting (B) is usually reserved for documented significant pressure gradients and bilateral or dominant-sided stenosis; here the right sinus is small and nondominant. Topiramate (C) is an adjunct but insufficient alone given progressive visual decline. Anticoagulation (E) is not indicated without imaging evidence of thrombosis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The clinical presentation is consistent with Idiopathic Intracranial Hypertension (IIH) (also known as pseudotumor cerebri). The patient meets the modified Dandy criteria: signs and symptoms of increased ICP (headache, TVOs, pulsatile tinnitus, papilledema), no localizing neurologic signs, normal MRI/MRV regarding space-occupying lesions or thrombosis (see below), and elevated opening pressure with normal CSF composition.\n\nThe critical factor in this scenario is the progressive visual field loss despite medical management (acetazolamide and weight loss). This indicates medically refractory IIH with a threat to vision, which is an indication for surgical intervention.\n\nLet's evaluate the options:\n\n*   A. Place a ventriculoperitoneal (VP) shunt: While shunting (VP or lumboperitoneal) is effective for lowering global ICP and treating both headaches and papilledema, VP shunts can be technically difficult to place in IIH patients due to typically small or \"slit-like\" ventricles (normal brain anatomy). Shunts also have a high rate of failure, infection, and need for revision.\n*   B. Perform right transverse sinus stenting: Venous sinus stenting is indicated when there is a hemodynamically significant stenosis (pressure gradient) in the dominant transverse sinus or usually bilateral stenosis. The MRV description here shows a hypoplastic/atretic right sinus (\"smooth tapering and non-visualization\") and a dominant and widely patent left sinus. Since the dominant outflow tract is \"widely patent\" (no stenosis), there is no target for stenting that would relieve the intracranial pressure. Stenting is not indicated in the absence of a demonstrable stenosis in the primary outflow pathway.\n*   C. Initiate high-dose oral topiramate: While topiramate is used in IIH (often for headache prevention and its side effect of weight loss), changing medication is insufficient for progressive visual loss. This is a surgical emergency to prevent blindness.\n*   D. Perform optic nerve sheath fenestration (ONSF): ONSF is the typically preferred surgical intervention for IIH patients with progressive visual loss (threatened vision) who have failed or are intolerant to medical therapy. It rapidly decompresses the fluid in the nerve sheath, reducing papilledema and stabilizing vision in >90% of cases. While it is less reliable for headache control compared to shunting, the priority here is the documented progressive loss of visual fields. ONSF has a lower rate of serious complications compared to shunting.\n*   E. Start therapeutic anticoagulation: The MRV findings (\"smooth tapering\") are characteristic of congenital hypoplasia or stenosis associated with IIH, rather than acute or chronic venous sinus thrombosis (which would show filling defects, delta sign, or lack of flow in a previously patent sinus). Furthermore, the left sinus is patent. Anticoagulation is not the treatment for IIH.\n\nGiven the progressive visual loss, the most appropriate next step is to protect the optic nerve directly.\n\nThe answer is (D)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-008", "question": "A 29-year-old woman with a history of two early first-trimester miscarriages and one unexplained fetal demise at 28 weeks presents for preconception counseling. She has livedo reticularis and episodes of digital ischemia in cold weather. Labs: platelets 110,000/µL, hemoglobin 11.5 g/dL, creatinine 0.9 mg/dL. Coagulation profile is normal. aPTT is mildly prolonged. Lupus anticoagulant is repeatedly positive; anticardiolipin IgG and anti-β2-glycoprotein I IgG are high-titer on two occasions 12 weeks apart. She has no personal history of venous or arterial thrombosis. Which of the following is the most appropriate pregnancy management plan?", "options": ["Low-dose aspirin alone starting preconception, escalate to prophylactic LMWH only if thrombosis occurs", "Therapeutic-dose LMWH plus low-dose aspirin starting at positive pregnancy test and continuing 6 weeks postpartum", "Prophylactic-dose LMWH plus low-dose aspirin starting at conception and stopping at delivery", "Low-dose aspirin only during pregnancy, with postpartum prophylactic LMWH for 6 weeks", "No anticoagulation unless she develops hypertensive disorders of pregnancy"], "answer": "B", "answer_index": 1, "explanation": "She meets criteria for high-risk obstetric antiphospholipid syndrome with recurrent pregnancy loss and triple-positive aPL; therapeutic-dose LMWH plus low-dose aspirin throughout pregnancy and 6 weeks postpartum provides optimal maternal and fetal protection. Aspirin alone (A, D, E) is inadequate in high-risk APS. Prophylactic-dose LMWH (C) may be used in lower-risk obstetric APS but is insufficient here given triple positivity and prior late fetal loss and thrombocytopenia suggestive of high thrombotic risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient has a diagnosis of Obstetric Antiphospholipid Syndrome (OAPS).\n\n1.  Diagnosis: Her history includes one unexplained fetal demise at 28 weeks (occurring after 10 weeks gestation), and two early miscarriages. She also has triple-positive antiphospholipid antibodies (Lupus Anticoagulant, high-titer Anticardiolipin, high-titer Anti-$\\beta$2-glycoprotein I). This meets the clinical and laboratory criteria for APS. Crucially, the prompt states she has no personal history of venous or arterial thrombosis.\n2.  Risk Stratification: The patient has a \"high-risk\" serologic profile (triple positive) and non-criteria manifestations (livedo, thrombocytopenia), but she does not have a history of a confirmed thrombotic event (DVT, PE, stroke).\n3.  Management Principles:\n    *   Low-Dose Aspirin (LDA) alone is generally considered insufficient for patients with a history of late fetal loss (Option A and D are incorrect).\n    *   Therapeutic-dose LMWH is associated with higher bleeding risks and is reserved for patients with \"Thrombotic APS\" (history of vascular thrombosis) or those who fail prophylactic anticoagulation. Since she has no history of thrombosis, therapeutic dosing is inappropriate (Option B is incorrect).\n    *   Prophylactic-dose LMWH plus Low-Dose Aspirin is the standard of care for women with Obstetric APS, especially those with a history of fetal death (>10 weeks). This regimen improves live birth rates and reduces the risk of placental thrombosis/insufficiency.\n    *   Postpartum Management: Women with APS are at high risk for thrombosis postpartum and typically require anticoagulation for 6–12 weeks. While Option C states \"stopping at delivery,\" it describes the correct antepartum drug and dosage (Prophylactic LMWH + Aspirin), which is the primary intervention for preventing the recurrence of her fetal demise. Option B has the correct postpartum duration but the wrong (unsafe) dosage for her indication. In multiple-choice questions regarding APS, distinguishing between prophylactic (for obstetric history) and therapeutic (for thrombotic history) dosing is the most critical concept. Therefore, Option C is the best answer provided, assuming \"stopping at delivery\" refers to the cessation of the pregnancy-specific protocol before labor (to manage bleeding risk) or is a limitation of the question options, as therapeutic dosing is contraindicated without thrombotic history.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-009", "question": "A 55-year-old man from a region endemic for Lyme disease presents with 1 week of rapidly progressive bilateral leg weakness and numbness ascending from the feet, severe radicular pain, and new urinary retention. He was treated with oral doxycycline 3 weeks ago for erythema migrans following a hiking trip. Exam: symmetric lower extremity weakness 3/5 proximally and distally, hyperreflexia with bilateral Babinski signs, decreased pinprick below T10, preserved vibration sense in toes, and saddle hypesthesia. Cranial nerves are normal. MRI spine with contrast: multifocal enhancing lesions in the thoracic cord with associated leptomeningeal enhancement; no compressive lesion. CSF: WBC 220/µL (80% lymphocytes), protein 120 mg/dL, glucose 45 mg/dL (serum 90), oligoclonal bands present; CSF Lyme antibody index is elevated. HIV, syphilis, and TB tests are negative. What is the most appropriate treatment?", "options": ["High-dose IV methylprednisolone alone for presumed idiopathic transverse myelitis", "IV ceftriaxone 2 g daily for 4 weeks without steroids", "IV ceftriaxone 2 g daily plus high-dose IV methylprednisolone", "Oral doxycycline 100 mg BID for 28 days plus high-dose oral prednisone taper", "Plasma exchange for 5-7 sessions followed by IV ceftriaxone"], "answer": "B", "answer_index": 1, "explanation": "This is Lyme neuroborreliosis with meningomyelitis confirmed by elevated CSF Lyme antibody index and appropriate clinical picture; standard treatment is prolonged IV ceftriaxone without routine adjunctive steroids. Steroids alone (A) are inappropriate and may worsen infection. Adding high-dose steroids to antibiotics (C) has no proven benefit and may be harmful. Oral doxycycline (D) is inadequate for CNS parenchymal involvement. Plasma exchange (E) is used in severe autoimmune demyelination (e.g., NMO, ADEM) and is not indicated here once Lyme is confirmed.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with signs and symptoms consistent with Lyme myelitis (a form of Lyme neuroborreliosis), characterized by rapidly progressive paraparesis, sensory level, autonomic dysfunction (urinary retention), and evidence of parameningeal/parenchymal spinal cord inflammation (multifocal enhancing lesions, leptomeningeal enhancement). The diagnosis is confirmed by the lymphocytic pleocytosis with elevated protein, hypoglycorrhachia (low glucose), and, crucially, a positive CSF Lyme antibody index (demonstrating intrathecal antibody production).\n\nRegarding treatment:\n1.  Antimicrobial agents: The 2020 IDSA/AAN/ACR guidelines recommend intravenous (IV) ceftriaxone, cefotaxime, or penicillin G for patients with Lyme disease-associated parenchymal involvement of the brain or spinal cord. While oral doxycycline is considered non-inferior for Lyme meningitis and radiculoneuritis, IV antibiotics are preferred for parenchymal involvement (encephalomyelitis). Furthermore, this patient already received a course of oral doxycycline 3 weeks ago (likely for the erythema migrans), and the development of severe neurologic symptoms suggests either treatment failure, insufficient CNS penetration/levels with the previous oral regimen, or non-compliance; therefore, IV therapy is indicated.\n2.  Corticosteroids: The use of broad immunosuppression with corticosteroids in Lyme neuroborreliosis is generally not recommended. Guidelines suggest against adjunctive corticosteroids because they have not shown clear benefit and may theoretically hinder host immune clearance of the spirochete. While some clinicians might consider them in rare cases of severe spinal cord swelling with compression (not present here per MRI) or severe vasculitis, the standard \"best appropriate\" answer for board examinations is antibiotic therapy alone. There is no proven benefit to adding steroids, and option B specifically specifies \"without steroids,\" distinguishing it as the guideline-concordant choice over option C.\n\nTherefore, the most appropriate treatment is IV ceftriaxone alone.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-010", "question": "A 48-year-old woman with seropositive rheumatoid arthritis (RF and anti-CCP positive) on methotrexate and adalimumab presents with subacute dyspnea and nonproductive cough. She has never smoked. Vitals: HR 104, BP 118/70, RR 22, SpO2 91% RA. Exam: fine bibasilar crackles, no wheezing, active small-joint synovitis. PFTs: FVC 58% predicted, FEV1/FVC 0.86, DLCO 35% predicted. HRCT: basilar-predominant reticulation, traction bronchiectasis, and patchy subpleural honeycombing consistent with usual interstitial pneumonia (UIP); no nodules or pleural effusions. Which of the following is the most appropriate disease-modifying management change?", "options": ["Continue methotrexate and adalimumab and add low-dose prednisone", "Discontinue methotrexate and switch adalimumab to rituximab", "Stop adalimumab and start tocilizumab while continuing methotrexate", "Continue current RA regimen and initiate mycophenolate mofetil for lung disease", "Add nintedanib while continuing methotrexate and adalimumab unchanged"], "answer": "B", "answer_index": 1, "explanation": "She has RA-associated ILD with a UIP pattern, in which methotrexate and TNF inhibitors are relatively contraindicated due to concerns for ILD progression; rituximab is preferred as an RA biologic in ILD. Continuing MTX/TNF with steroids (A) risks worsening lung fibrosis. Tocilizumab (C) has less data and does not address TNF-risk concerns. Adding mycophenolate (D) without removing potential pulmonary offenders is suboptimal. Nintedanib (E) may be beneficial in progressive fibrosing RA-ILD, but first-line is to remove MTX/TNF and choose an ILD-favorable biologic such as rituximab.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The clinical presentation is consistent with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) presenting with a usual interstitial pneumonia (UIP) pattern. The patient has seropositive RA (RF and anti-CCP positive) with active synovitis and severe impairment of gas exchange (DLCO 35% predicted) while on methotrexate and adalimumab (a TNF inhibitor).\n\n1.  Assessment of Current Regimen:\n    *   Adalimumab (TNF inhibitor): TNF inhibitors have been associated with the development or exacerbation of ILD in patients with RA. In patients with established or worsening RA-ILD, guidelines and expert consensus generally recommend switching away from TNF inhibitors to other mechanisms of action.\n    *   Methotrexate (MTX): Historically, MTX was considered a major cause of lung toxicity. Recent evidence and the 2022 ACR guidelines suggest that MTX is not associated with an increased risk of chronic ILD and may be continued in RA-ILD. However, in patients with severe respiratory impairment (DLCO 35%) or subacute worsening, many clinicians choose to discontinue MTX to eliminate any potential contribution to pulmonary toxicity (such as hypersensitivity pneumonitis, though the imaging here suggests UIP) or simply to minimize pill burden/toxicity when starting a potent biologic.\n\n2.  Selection of New Therapy:\n    *   Rituximab: There is substantial observational evidence suggesting that Rituximab (an anti-CD20 monoclonal antibody) is effective in stabilizing lung function in RA-ILD and controlling articular disease, particularly in seropositive patients (like this woman). It is a preferred biologic for patients with RA-ILD who have had an inadequate response or intolerance to other agents, or where TNFi are contraindicated due to lung disease.\n    *   Tocilizumab and Abatacept are also considered safer alternatives to TNFi, but Rituximab is often the first choice in seropositive RA-ILD.\n    *   Mycophenolate (MMF): While used for CTD-ILD, adding it without addressing the potentially deleterious TNFi and the active joint disease (which might require a biologic switch anyway) is not the optimal strategy.\n    *   Nintedanib: An antifibrotic indicated for progressive fibrosing ILD. While appropriate for the lung fibrosis, it does not treat the active articular inflammation (synovitis) and does not address the need to stop the TNFi. It functions best as an add-on therapy after the immunosuppressive regimen is optimized, not as the primary \"disease-modifying management change\" for the systemic disease.\n\n3.  Evaluating the Options:\n    *   Option B (Discontinue methotrexate and switch adalimumab to rituximab) is the best choice. It removes the TNFi (which may be driving the ILD worsening) and introduces Rituximab, which is highly effective for seropositive RA joints and is the most evidence-based biologic for stabilizing RA-ILD. Discontinuing methotrexate is a reasonable precautionary step in the setting of severe pulmonary impairment and is commonly paired with the initiation of Rituximab in board-style questions regarding severe RA-ILD.\n\nThe answer is (B)"}]